Optimizing Access to Monoclonal Antibodies for COVID-19 Infection: The Global Perspective

Optimizing Access to Monoclonal Antibodies for COVID-19: US PerspectiveПодробнее

Increasing Use of Monoclonal Antibodies Treatment of COVID 19 (Feb. 11, 2021)Подробнее

COVID-19 Update: Monoclonal Antibody TreatmentПодробнее

Challenges and Opportunities in the Use of Monoclonal Antibody Therapy for COVID-19Подробнее

IAVI’s Global Call to Access for Monoclonal Antibodies for COVID-19 and Other DiseasesПодробнее

Live Q&A: Monoclonal Antibodies Treatment for COVID-19Подробнее

Monoclonal Antibodies for COVID-19 in Africa: Promise and PitfallsПодробнее

Benefits of Monoclonal Antibody TreatmentПодробнее

Monoclonal Antibody Therapy: COVID-19 TreatmentПодробнее

Evidence Update and Practical Perspectives: Monoclonal Antibodies for COVID-19 TreatmentПодробнее

Equitable Access to Monoclonal Antibody Treatmentfor COVID-19Подробнее

What are monoclonal antibodies? Infectious disease specialists help explainПодробнее

Strengthening regulatory and policy frameworks to enable access to monoclonal antibodies in AfricaПодробнее

Monoclonal Antibodies for COVID-19: Who, When, and How?Подробнее

Treating High-Risk COVID-19 Patients with Monoclonal AntibodiesПодробнее

COVID-19 Virtual Briefing Series Session 8: Monoclonal Antibody Therapy for COVID-19 Latino PatientsПодробнее

Monoclonal antibodies and can they treat coronavirusПодробнее

Gov. Cooper expands access to monoclonal antibody treatment for COVID-19Подробнее

Practices for Improving the Use of COVID-19 Monoclonal AntibodiesПодробнее